Summary An autoimmune basis for the pathogenesis of insulin-dependent diabetes mellitus (IDDM) is supported by the frequent presence of autoantibodies ± islet cell antibodies (ICAs) and GAD antibodies (GADab). However, in Chinese patients with clinical IDDM, a low prevalence of ICAs was observed. In non-insulin-dependent diabetic (NIDDM) patients, it has been suggested that the presence of GADab may identify a subset of latent autoimmune diabetes in adults (LADA). We determined the frequency of GADab in a large group of 134 IDDM and 168 NID-DM Chinese patients, and assessed the relation with ICAs status. Results showed that 39.6 % IDDM and 16.1 % NIDDM patients had GADab, and 20.1 % and 4.8 %, respectively had detectable ICAs. Frequency of GADab positivity was not influenced by whether the patients had youth or adult-onset its relation with ICA status, in a large group of IDDM and NIDDM patients.
Subjects and methods
Patients. Subjects were recruited from the Diabetes Clinic at our tertiary referral hospital. Venous blood was obtained in the morning by venepuncture, left to clot at 4°C and the serum immediately separated and stored at ±70°C. We studied 134 patients with IDDM (51 males, 83 females) and 168 patients with NIDDM (97 males, 71 females).
We used World Health Organisation criteria for diagnosis of IDDM and NIDDM [13] . Patients with IDDM are diagnosed on the basis of classical presentation of acute abrupt symptoms and (i) with diabetic ketoacidosis at diagnosis or (ii) with the patient requiring insulin treatment at diagnosis, and continuously for 1 year. Patients who did not fall into either of these two criteria were classified as having NIDDM. Those patients who could not be assigned clearly as IDDM or NIDDM were not included in the data analyses. Less than 7 % (22/324) of our study cohort belongs to this`intermediate group'.
Measurement of C-peptide. Serum C-peptide levels were measured by a double antibody radioimmunoassay (Diagnostic Products Corporation, Los Angeles, Calif., USA). Serum samples (25 ml) were incubated with competing 125 I-labelled Cpeptide and antiserum for 4 h at room temperature. The separation of bound from free was achieved by a polyethyleneglycol (PEG)-accelerated double antibody method. Precipitated antibody-bound fraction was then counted and the patient sample concentrations read from a calibration curve. The test has a detection limit of 0.07 nmol/l.
Detection of cytoplasmic ICA. Islet cell antibodies were detected by the indirect immunofluorescence technique as described previously [14] , using unfixed cryostat sections. The same tissue was used for all determinations. The assay has a sensitivity of 5 Juvenile Diabetes Foundation Units (JDF-U) with the results reported here as positive ( > 5 JDF-U) or negative.
Detection of antibodies to GAD. Antibodies to GAD were measured by ELISA using the capture antibody method. Microplates (Maxisorp immunoplates; Nunc A/S, Roskilde, Denmark) were first coated with 50 ml GAD-1 monoclonal antibody (Chemicon Inc., Tumecula, Calif., USA), diluted 1:2000 in 0.1 mol/l bicarbonate buffer pH 9.6, overnight at 4°C. The assay wells were drained and non-specific binding sites blocked with 100 ml 2 % non-fat milk (NFM)/phosphate buffered saline (PBS) for 2 h at 37°C. After washing with PBS/ Tween 20 three times, 50 ml rat brain homogenate was added to alternate duplicate wells and left to incubate for 2 h at 37°C with constant shaking. Following washing, 50 ml diluted serum (1:50 in NFM/PBS) was added to the quadruplicate wells (with/without rat brain homogenate coating) for a further 2 h incubation at 37°C with constant shaking. Horseradish peroxidase conjugated rabbit anti-human immunoglobulins (50 ml, diluted 1/2000 in NFM/PBS; DAKO A/S, Glostrup, Denmark) was then added for another 2 h at 37°C with shaking. After washing, the reaction was developed with 50 ml of substrate (2 mmol/l ABTS, 2,2 ′-azino-di-[3-ethylbenzthiazoline sulfonate (6) ] in citrate phosphate buffer pH 5.0; Boehringer Mannheim GmbH, Mannheim, Germany) for 30 min at 37°C with shaking. The optical density was read in a Dynatech MR700 automated plate reader (Burlington, Mass., USA) at 410 nm with 630 nm as reference. The difference in the mean optical density obtained in duplicate assay wells, with and without homogenate-coating, was calculated and expressed in relative units ( × 10 ±3 OD). The cutoff level (2 SD) was determined with 52 healthy subjects: more than 10 relative units (RU) was considered positive for GAD antibodies. Results are reported here as positive ( > 10 RU) or negative. This assay procedure achieved 100 % specificity and 75 % sensitivity at the first GADab proficiency programme.
Statistical analysis. Data were analysed by SPSS/PC + software (SPSS Inc., Chicago, Ill., USA). The significance of differences between observations was assessed using the chi-square test or Fisher's exact probability test where appropriate. Mean values differences were assessed by the Student's t-test.
Results
Clinical characteristics in patients with IDDM and NIDDM, are described in Table 1 . The mean ages of IDDM and NIDDM patients tested were 22.1 and 40.6 years, and duration of diabetes 4.6 and 2.3 years, respectively. The IDDM patients had significantly lower mean BMI (19.2 ± 3.9 kg/m 2 ) compared to the NIDDM (24.4 ± 4.0 kg/m 2 ). Only 7 of 134 IDDM patients were obese with BMI 25 kg/m 2 or more, their mean age at onset was 18.8 ± 5.3 years and 5 patients had age-onset 20 years or less. Forty-eight patients with IDDM had a history of ketoacidosis (DKA) at presentation and none of the patients with NIDDM had DKA. All patients with IDDM were on insulin treatment since diagnosis and remained on this modality continuously with no patients reverting to diet or oral agents. Thirty-two of the 168 patients with NIDDM were insulin requiring because of secondary drug failure, while the rest were treated with diet alone or oral hypoglycaemic agents at time of study. Seventy (52.2 %) and 118 (70.2 %) patients with IDDM and NIDDM respectively, had a short duration diabetes ( < 1 year), while the remaining 64 Autoantibodies in IDDM. GADab were detected in 53 of 134 (39.6 %) patients with IDDM. The frequency of positive GADab was not influenced by whether patients had youth-onset IDDM (46/119, 38.7 %) or adult-onset IDDM (7/15, 46.7 %), or by whether diabetes was of short (31/70, 44.3 %) or longer (22/64, 34.4 %) duration.
GADab was not associated with a history of DKA, being detected in 43.8 % of those patients with DKA and 37.2 % without DKA, which was not significantly different. This lack of association with DKA was also found when results were analysed in those patients with younger age at onset ( ≤ 20 years) of IDDM.
Females (39/83, 47.0 %) had a higher GADab positivity rate compared to males (14/51, 27.5 %; p = 0.019). The mean age at testing for the females was not different from males (20.7 ± 12.8 vs 24.0 ± 7.7 years, p = 0.370).
Compared to GADab, ICA was detected in a lower (27/ Sixty-three (47.0 %) patients were seropositive for either GADab or ICAs, while 17 (12.7 %) patients had both antibodies. Thus a high proportion (71/134, 53 %) of IDDM patients were negative for both of these autoimmune markers.
Autoantibodies in NIDDM. GADab were detected in 27 of 168 (16.1 %) and ICAs in 8 of 168 (4.8 %) of patients with NIDDM. Prevalence rates for GADab were not related to whether NIDDM was of youth (9/54, 16.7 %) or adult onset (18/114, 15.8 %), or with short (18/118, 15.3 %) or long (9/50, 18.0 %) duration of diabetes. These observations were also shown with the prevalence rates for ICAs: youth onset (3/54, 5.6 %), adult onset (5/114, 4.4 %), short duration (3/118, 2.5 %) and long duration diabetes (5/50, 10.0 %). Prevalence rates for GADab and ICAs were also not different in males (GADab: 17/ 97, 17.5 %; ICAs: 4/97, 4.1 %) compared to females (GADab: 10/71, 14.1 %; ICAs: 1/71, 1.4 %). Thirty (17.9 %) patients were seropositive for either GADab or ICAs, and only 4 (2.4 %) for both antibodies. Table 3 compares the clinical characteristics of IDDM and NIDDM patients who were GADab positive or negative. There was no difference in ageonset, duration of diabetes, body mass index and fasting C-peptide levels in patients who were GADab Data given as mean ± SD; percent given in parentheses NS, Not significant; a p < 0.05 for youth-onset vs adult-onset and short vs long duration positive or negative, in both the IDDM and NIDDM patients.
When results were further analysed in which distinction between IDDM and NIDDM was removed, GADab was detected in 39 (35.5 %) of 110 patients with younger age at onset ( ≤ 20 years), and 41 (21.4 %) of 192 patients with older age at onset ( > 20 years) diabetes. In both groups of patients, GADab positivity was found to be associated with lower fasting C-peptide and lower BMI. This association can however be attributed to the observation that in the GADab-positive group, there were proportionately more patients with IDDM than NIDDM classified based on our clinical criteria, both in the younger age at onset (p = 0.04) and older age at onset (p = 0.001) patients.
GADab titre in NIDDM was similar to IDDM (31.3 ± 29.4 vs 42.6 ± 41.1 relative units). Six of 27 (22.2 %) GADab-positive NIDDM patients required insulin treatment for glycaemic control compared to 26 of 141 (18.9 %) GADab-negative NIDDM patients, which was not statistically significant.
Discussion
Antibodies to glutamate decarboxylase were positive in 40 % of our cohort of IDDM patients. This figure for GADab positivity is lower compared to European and North American figures. In Caucasians, GADab are found in 60±90 % of recent-onset IDDM patients [1±4]. However, our figure for Chinese IDDM patients is consistent with a generally lower prevalence of IDDM-associated autoantibodies in Asians. Studies with small patient cohorts showed GADab prevalence rates of only 5±29 % in Japanese, Koreans, Thais and Chinese residents of Hong Kong [15, 16] . These observations were subsequently repeated by Tuomi et al. [12] . More recently, Rattarasarn et al. [17] showed that the prevalence of GADab in 39 Thai IDDM patients was 48.7 %, being slightly lower (35.7 %) in those of young-onset IDDM. In Japanese, high rates similar to the Caucasians for GADab were reported [18, 19] . However in a multicentre study, Tsuruoka et al. [20] found a GADab positivity rate of 35.4 % in 921 Japanese IDDM patients studied, and among those with newly diagnosed diabetes, 50.3 % of the patients had detectable GADab.
Our study showed similar frequencies of GADab in patients with recent-onset IDDM (44.3 %) compared with those with longer duration of diabetes (34.4 %). This would support the view that GADab declines slowly and persists in the circulation for years, unlike ICAs. Duration of IDDM was also observed by Myers et al. [21] to have little effect on the frequency of GADab. Vandewalle et al. [22] found GADab in IDDM patients of older (20±40 years) age-onset diabetes were higher (19/45, 42.2 %) than in those of younger age-onset ( ≤ 20 years) patients (31/82, 37.8 %). Our study showed that GADab were equally frequent in young or older-onset IDDM patients.
Chan et al. [16] reported their findings of anti-GAD antibodies in a small cohort of 39 Chinese patients with IDDM, with mean ± SD age of 37 ± 15 years. Our larger cohort of 134 IDDM patients studied had a younger mean age of 22.1 ± 12.9 years. Duration of diabetes in both studies was quite similar, i. e. 6.7 ± 5.6 compared to 4.6 ± 6.6 years respectively. The authors found a prevalence rate for GADab positivity of 23.1 % and an association between anti-GAD positivity with younger age, earlier age of onset and lower BMI while we did not find this association. An explanation for this discrepant finding is that Chan et al.'s IDDM patients were older compared to our cohort, and were relatively more heterogenous with regards to their clinical characteristics and the status of pancreatic beta-cell function compared to Data given as mean ± SD a C-peptide levels from fasting specimens only available for a subgroup of patients our IDDM patients. Ten (25.6 %) of the 39 IDDM patients were non-insulin-deficient (mean fasting Cpeptide 0.76 nmol/l), and were older, had later age at onset and higher BMI compared to the insulin-deficient IDDM (mean fasting C-peptide 0.15 nmol/l). It is therefore not surprising that the anti-GAD positive patients were confined to the insulin-deficient patients and none of the non-insulin-deficient patients were positive for anti-GAD. In comparison, the majority (88.8 %) of our IDDM patients had young-onset (age ≤ 30 years) IDDM, while only a small proportion had adult-onset IDDM, and fasting C-peptide in these two sub-groups was not different (0.27 vs 0.22 nmol/l). Our study also suggests that GADab in IDDM may be gender-related being more frequent in females than males. This association has also been shown by Schmidli et al. [23] with results showing that post-pubertal females with at-risk and clinical IDDM, compared to males, had an association with GADab. This indicates that GAD autoantibody response may be operating differently at different ages, and may also be gender related [24] .
Prevalence of ICAs was detected in only 20 % of our IDDM patients. We did not find an association between ICAs and GADab, in contrast to observations reported [23, 25] .
For NIDDM patients, we found prevalence rates for GADab of 16.1 % and ICAs of 4.8 %. In 133 recent onset Finnish NIDDM patients aged 45± 64 years, 9 % had GADab and 3.8 % had ICAs [7] . Among the Wanigela people of Papua New Guinea, where susceptibility to NIDDM is high, a study of 93 newly diagnosed NIDDM diabetic patients showed no evidence of GADab [26] .
Studies reported that 4.3 % in 680 Japanese NID-DM had GADab [20] , and in a smaller cohort of 24 Thai NIDDM, 8.3 % had GADab [17] . In Koreans, 1.7 % of 121 recent onset NIDDM patients (mean age 57 years) had GADab [11] , a figure much lower than the GADab frequency of 15.3 % in our recentonset NIDDM patients.
It was suggested that GADab may identify a latent form of insulin-dependency in NIDDM patients or LADA [6, 7] . However, in our GADab-positive NID-DM, 22.2 % (6/27) required insulin treatment, compared to 26 of 141 (18.4 %) in the GADab-negative sub-group, which was not statistically significant. None of the patients with NIDDM had primary drug failure requiring insulin treatment. Moreover, our NIDDM GADab-positive patients had similar ageonset, sex distribution, duration and fasting C-peptide level as in NIDDM GADab-negative patients. Our finding thus suggests that seropositivity for GADab in NIDDM does not help to distinguish a subgroup who may have latent or slow-onset IDDM.
A high (53 %) proportion of Chinese IDDM patients, has no evidence of either GADab or ICAs. This suggests that differences in aetiology may exist between racial groups. It is noteworthy that in a study of about 100 Danish patients with recent-onset IDDM measured for GADab and ICAs, findings suggest that some late-onset patients (after 30 years of age), with sera negative for ICAs, may not have an autoimmune pathogenesis [4] . It is however, also possible that other autoantigens yet to be identified, may be of greater relevance in the Chinese. HLA associations in Chinese IDDM patients have been shown to be gender-and age-related, DRB1*0301/0901 observed mainly in females and DRB1*0301/04 in males, with an inverse relationship seen with age-atonset for both sexes [27] . HLA associations in Chinese IDDM may be different from those in Caucasians [27, 28] . For example, the frequency of DQB1*0302 (NAsp57) a high-risk allele associated with Caucasians was not increased in our patients compared to controls [27] . Decreasing influence of HLA class II susceptibility alleles with increasing age at onset also point to a less critical role for the immune system in these patients [4] .
